Exicure, Inc. (XCUR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. on May 11, 2023, covering events occurring on May 8 and May 10, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Chicago, Illinois. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "XCUR."
Key Financial Metrics
This filing does not contain specific revenue, profit, cash flow, or debt figures for the current period. However, it references prior audit reports from KPMG LLP for the years ended December 31, 2022, and 2021, which included a "Going Concern" qualification. The auditors noted that the Company has incurred significant expenses and negative cash flows since inception, and its current liquidity is not sufficient to fund operations over the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Material Changes and Events
- Nasdaq Delisting Notice (Item 3.01): On May 10, 2023, the Company received notice from Nasdaq that it is no longer in compliance with Listing Rule 5605 regarding audit committee requirements. This non-compliance stems from the resignation of Hyukku Lee as an independent director, effective May 3, 2023. The rule requires at least three independent directors on the audit committee.
- Accountant Resignation (Item 4.01): On May 8, 2023, KPMG LLP resigned as the Company's independent registered public accounting firm, effective immediately. There were no disagreements between the Company and KPMG regarding accounting principles, practices, or audit scope prior to the resignation.
Outlook, Risks, and Management Commentary
Cure Period for Listing Compliance: The Company has been granted a cure period to regain compliance with Nasdaq's audit committee requirements. This period expires at the earlier of the 2023 Annual Meeting of Stockholders or May 3, 2024. If the Annual Meeting is held before October 30, 2023, compliance must be evidenced by that date. Management intends to appoint a qualified independent director to the Board and Audit Committee prior to the end of this cure period.
Liquidity Risk: The filing reiterates the substantial doubt regarding the Company's ability to continue as a going concern due to insufficient liquidity to fund operations for the next twelve months, as previously disclosed in financial statement notes.
Investor Verification Checklist
- Verify the timeline for the appointment of a new independent director to satisfy Nasdaq Rule 5605.
- Confirm the date of the 2023 Annual Meeting of Stockholders to determine the exact deadline for curing the listing deficiency.
- Review the Company's subsequent filings for the engagement of a new independent registered public accounting firm to replace KPMG LLP.
- Monitor updates regarding the Company's liquidity position and any capital raising activities to address the "Going Concern" uncertainty.